Repligen (RGN) Price & Analysis
RGN Stock Chart & Stats
- Day’s Range
- EUR 155.70 - EUR 169.50
- 52-Week Range
- EUR 86.32 - EUR 170.65
- Previous Close
- EUR 170.20
- Volume
- 0
- Average Volume (3M)
- 1
- Market Cap
- EUR 10.03B
- Enterprise Value
- EUR 10.70B
- Total Cash (Recent Filing)
- EUR 862.98M
- Total Debt (Recent Filing)
- EUR 692.24M
- Price to Earnings (P/E)
- ―
- Beta
- 0.97
- Next Earnings
- Feb 24, 2027
- EPS Estimate
- 0.47
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Consumables Model
Validated consumables and replaceable process components can create repeat purchasing and customer stickiness. Revalidation requirements make switching less attractive, supporting recurring revenue, durable account relationships, and more predictable demand as biologics manufacturing expands.
Cash Generation And Balance Sheet
Strong operating and free cash flow provide internal funding for investment, acquisitions, and debt service. Combined with moderate leverage and substantial equity, this gives Repligen financial flexibility to pursue growth while absorbing normal business volatility.
Diversified Growth Platform
Growth across bioprocessing franchises and the completed BioLife acquisition broadens Repligen’s exposure to cell therapy and other expanding modalities. The combination of organic growth and complementary capabilities supports a larger, more diversified long-term revenue base.
Bears Say
Weak Net Profitability
Negative net income reduces earnings quality and makes reported profitability less reliable despite positive operating cash flow and EBITDA. Margins below prior peaks indicate that the company has not yet fully restored its former earnings power or operating efficiency.
Filtration And Equipment Headwinds
Filtration weakness directly pressures an established product franchise, while delayed equipment conversion pushes recognized revenue into later periods. These issues can make near-term growth uneven and increase reliance on stronger chromatography, protein, and analytics performance.
Convertible Financing And Dilution
The refinancing extends maturities and raises cash, but the large convertible issuance adds future dilution risk if conversion occurs. It also increases the complexity of capital allocation and may constrain per-share benefits from otherwise successful operating growth.
Repligen News
RGN FAQ
What was Repligen’s price range in the past 12 months?
What is Repligen’s market cap?
When is Repligen’s upcoming earnings report date?
How were Repligen’s earnings last quarter?
Is Repligen overvalued?
Does Repligen pay dividends?
What is Repligen’s EPS estimate?
How many shares outstanding does Repligen have?
What happened to Repligen’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Repligen?
What is the TipRanks Smart Score and how is it calculated?
Repligen Stock Smart Score
Company Description
Repligen
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Olivier Loeillot
- Employees
- 2,000
- Website
- www.repligen.com
- Address
- Building 1, Waltham, MA, 02453, US
Repligen (RGN) Earnings & Revenues
RGN Company Deck
RGN Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall. Repligen reported record revenue, double-digit organic growth, operating margin expansion, higher full-year guidance, strong demand in chromatography, proteins, analytics, China, services, and capital equipment orders, and encouraging early progress integrating BioLife. The company acknowledged meaningful challenges, including an 11% filtration decline, delayed equipment revenue conversion, a 30-basis-point gross margin decline, customer decision delays, and on-shoring projects running 9 to 12 months behind expectations, but management expressed confidence in the 2027 outlook and continued market-share and growth opportunities.
View all DE:RGN earnings summariesRGN Net sales Breakdown
- 44.00% North America
- 37.00% Europe
- 19.00% APAC/Other
RGN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 5 | 6 |
| Technical Analysis | 5 | 5 | 0 |
| Moving Averages | 6 | 0 | 6 |